Plain-English translation of NCT06239727 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with stage III nasopharyngeal cancer can safely receive lower doses of radiation therapy combined with chemotherapy and camrelizumab (an immunotherapy medication) instead of the standard higher radiation doses. The study will enroll people whose cancer shows a complete response after the first part of radiation treatment, then randomly assign them to receive either the reduced or standard radiation dose to see if both work equally well.
Standard radiation therapy for nasopharyngeal cancer can cause serious side effects that affect quality of life, including damage to nearby tissues and organs. This trial is testing whether reducing the radiation dose in patients whose cancers respond very well to initial treatment could lower these side effects while maintaining the same cancer-fighting results.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive three cycles of combination chemotherapy with camrelizumab (given every 3 weeks), followed by daily radiation therapy five days a week for about 6 weeks, with two additional chemotherapy cycles given during radiation. After radiation ends, your doctor will perform an MRI scan to check how well your cancer has responded. If your cancer is in complete remission, you will be randomly assigned to receive either reduced-dose or standard-dose radiation, and then continue with nine cycles of camrelizumab immunotherapy every 3 weeks. The entire treatment process takes several months, with regular hospital visits for treatment and monitoring.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China